In 3 of the 4 pivotal trials, 92%–94% of patients with EE healed—that’s the efficacy of NEXIUM 40 mg
In another study, 92% of patients were healed with NEXIUM 40 mg QD (n=576) vs 90% with omeprazole 20 mg QD (n=572)(P=NS)†4
In an additional study with NEXIUM 20 mg (n=587), 91% on NEXIUM 20 mg were healed compared to 88% on omeprazole 20 mg (n=588 ) P=NS†5
NEXIUM 40 mg, NEXIUM 20 mg, and omeprazole 20 mg are the FDA-approved doses for the healing of EE.
*Varying grades of EE defined as LA grades A, B, C, and D erosive esophagitis
†Data from multicenter, randomized, double-blind trials comparing oral doses of NEXIUM vs omeprazole, administered once daily to patients with endoscopically diagnosed EE.1-5
NEXIUM provided excellent healing of EE
‡Varying grades of EE defined as LA grades A, B, C, and D erosive esophagitis.
§Primary endpoint from a multicenter, randomized, double-blind, parallel-group, 8-week trial comparing oral doses of NEXIUM 40 mg with lansoprazole 30 mg, administered once daily to patients with endoscopically diagnosed EE.6
//Moderate-to-severe EE defined as LA grades C and D erosive esophagitis.
¶Primary endpoint from a multicenter, randomized, double-blind, parallel-group, 8-week trial comparing oral doses of NEXIUM 40 mg with lansoprazole 30 mg, administered once daily to patients with endoscopically diagnosed EE.7
NEXIUM 40 mg, NEXIUM 20 mg, and lansoprazole 30 mg are the FDA-approved doses for the healing of EE.
NEXIUM is contraindicated in patients with known hypersensitivity to any component of the formulation or to substituted benzimidazoles
Symptomatic response to therapy does not rule out the presence of gastric malignancy
Atrophic gastritis has occasionally been noted with long-term therapy with omeprazole
Long-term and multiple daily dose proton pump inhibitor (PPI) therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine
Hypomagnesemia has been reported rarely with prolonged treatment with PPI therapy and may require discontinuing PPI therapy
Concomitant use of NEXIUM and St. John's wort or rifampin can substantially decrease NEXIUM concentrations. Avoid concomitant use
Concomitant use of NEXIUM and atazanavir or nelfinavir is not recommended. NEXIUM may increase the plasma levels of saquinavir. Dose reduction of saquinavir should be considered
Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time. Esomeprazole may interfere with the absorption of drugs for which gastric pH affects bioavailability (eg, ketoconazole, iron salts, and digoxin)
NEXIUM may increase systemic exposure of cilostazol and one of its active metabolites. Consider dose reduction
NEXIUM I.V. should be used only when oral therapy with NEXIUM is not possible or appropriate
In adults, the most frequently reported adverse reactions (ARs) with NEXIUM include headache, diarrhea, and abdominal pain
The ARs reported at a frequency of 1% or greater with NEXIUM I.V. in clinical trials were headache, flatulence, nausea, abdominal pain, injection site reaction, diarrhea, dry mouth, dizziness/vertigo, constipation, and pruritus
In pediatric patients 1 to 17 years of age, the most frequently reported ARs with NEXIUM include headache, diarrhea, abdominal pain, nausea, and somnolence
Approved Uses
NEXIUM 40 mg and 20 mg are indicated for short-term treatment (4 to 8 weeks) in healing and symptomatic resolution of diagnostically confirmed erosive esophagitis (EE). NEXIUM 20 mg is indicated to maintain symptom resolution and healing of EE (controlled studies did not extend beyond 6 months), and for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with GERD.
You have unsuccessfully attempted to log in 3 times. If you forgot your password, click here. If you forgot the e-mail address used to create your account, call 888-692-9737, Monday through Friday, 8:30 am to 8:30 pm ET, excluding holidays.
Some content on AZ TouchPoints is available to registered users only. Once registered, you can use your e-mail address and password to log into any Web site powered by AZ TouchPoints.
You have unsuccessfully attempted to log in 3 times. If you forgot your password, click here. If you forgot the e-mail address used to create your account, call 1-800-236-9933, Monday through Friday, 8 am to 6 pm ET, excluding holidays.
Sorry, there are no Personal Account Specialists currently available.
If you would like information regarding products from AstraZeneca, please call the AstraZeneca Information Center at 1-800-236-9933, Monday through Friday, 8 am to 6 pm ET, excluding holidays.
We're sorry. This service is temporarily unavailable.
If you would like information regarding products from AstraZeneca,please call the AstraZeneca Information Center at 1-800-236-9933, Monday through Friday, 8 am to 6 pm ET, excluding holidays.
